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Hyperhomocysteinemia in Greyhounds and its Association with
Hypofolatemia and Other Clinicopathologic Variables
R.M. Heilmann, N. Gr€utzner, M. C. Iazbik, R. Lopes, C.S. Bridges, J.S. Suchodolski, C. G. Couto, and
J.M. Steiner
Background: Folate and cobalamin are essential cofactors for homocysteine (HCY) metabolism. Hyperhomocysteinemia,
a multifactorial condition, may reﬂect B vitamin deﬁciency and is associated with increased risk of cardiovascular disease,
thrombosis, and neurodegenerative and chronic gastrointestinal diseases in humans. Hyperhomocysteinemia has been
reported in Greyhounds with suspected chronic enteropathy.
Objectives: To evaluate the frequencies of and the association between hypofolatemia and hyperhomocysteinemia in
Greyhounds.
Animals: Data and serum samples from 559 Greyhounds.
Methods: Nested case-control study. The frequency of hypofolatemia in Greyhounds was determined by a laboratory
database search. The relationship between hyperhomocysteinemia (measured by gas chromatography-mass spectrometry) and
hypocobalaminemia and hypofolatemia was evaluated, and its frequency compared between healthy Greyhounds and Grey-
hounds with thrombosis or chronic diarrhea.
Results: Hypofolatemia was identiﬁed in 172 of 423 (41%) Greyhounds and was more common in hypo- than in normo-
cobalaminemic dogs (49% vs. 35%; P = .0064). Hyperhomocysteinemia was detected in 53 of 78 (68%) of Greyhounds, being
more common in hypo- than in normofolatemic dogs (88% vs. 59%; P = .0175). All healthy Greyhounds, 21 of 30 (70%) of
dogs with chronic diarrhea and 6 of 8 (75%) of those with thrombosis, were hyperhomocysteinemic. Serum HCY concentra-
tions were inversely correlated with serum folate concentration (q = 0.28; P = .0386) and were positively associated with
serum albumin concentration (q = 0.66; P = .0022).
Conclusions and Clinical Relevance: Hyperhomocysteinemia occurs frequently in the Greyhound population. Its associa-
tion with hypofolatemia suggests decreased intracellular availability of B vitamins, but the functional implications warrant
further investigation. Hyperhomocysteinemia in Greyhounds potentially may serve as a spontaneous canine model to further
investigate hyperhomocysteinemia in humans.
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A recent large database survey indicated thathypocobalaminemia is frequently observed in Grey-
hounds (40% compared to 21% in dogs of other
breeds).1 It is unknown whether intestinal malabsorp-
tion of cobalamin or other micronutrients (e.g, folate)
as a consequence of chronic gastrointestinal disease
may play a causative role for this ﬁnding in the breed.
Cobalamin (vitamin B12) and folate (vitamin B9) are
absorbed in the distal and proximal small intestine,
respectively, and decreased concentrations of both B
vitamins are usually a reﬂection of chronic gastrointesti-
nal disease associated with these intestinal segments.2
In humans, hypocobalaminemia and hypofolatemia
have been associated with an increase in serum concen-
trations of homocysteine (HCY), a sulfurated intermedi-
ate amino acid that is synthesized from dietary
methionine and then either remethylated to methionine
or metabolized to cysteine.3–5 The B vitamins folic acid
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(vitamin B9), cobalamin (vitamin B12), and pyridoxine
(vitamin B6) are essential cofactors for enzymes required
for HCY metabolism3–6 and for redox-methylation bal-
ance (methoxistasis).7 Hyperhomocysteinemia thus
reﬂects a lack of intracellular availability of cobalamin,
folic acid, or both for the synthesis of methionine4,5 and
represents a sensitive marker for the detection of B vita-
min deﬁciency5,6,8 and perturbation of methoxistasis.7
In humans, hyperhomocysteinemia is an incompletely
understood multifactorial condition.3–5 There is evidence
indicating that HCY has direct toxic eﬀects on neurons
and endothelial cells5,8 and that HCY can induce DNA-
strand damage, oxidative stress, and apoptosis.9 In line
with these ﬁndings, hyperhomocysteinemia has been
shown to be associated with cardiovascular disease and
with increased risk of venous and arterial thrombosis.4–6
Neurodegenerative diseases (e.g, cognitive impairment,
stroke), chronic gastrointestinal disease, and metabolic
and endocrine disorders have also been associated with
hyperhomocysteinemia in humans.4,5,8,10,11
Recently, cardiovascular and thrombotic diseases12–19
and an increased frequency of hypocobalaminemia1 also
have been described in Greyhounds. Furthermore,
hyperhomocysteinemia in dogs with suspected chronic
gastrointestinal disease is associated with hypocobal-
aminemia,20 which in turn has been linked to hypoalbu-
minemia.2,21 Thus, hypoalbuminemia may aﬀect
systemic HCY concentrations, as has been shown previ-
ously in people11 and dogs.22 It is unknown whether
low concentrations of cobalamin, folate, or both as well
as hyperhomocysteinemia, are present in Greyhounds
with chronic gastrointestinal disease, Greyhounds with
thrombotic disease, or healthy Greyhounds.
The aims of our study were to evaluate (1) the fre-
quency of hypofolatemia in hypocobalaminemic Grey-
hounds and (2) serum HCY concentrations in
hypocobalaminemic and hypofolatemic Greyhounds. As
a secondary aim of this study (3), serum HCY, cobal-
amin, and folate concentrations were evaluated in Grey-
hounds with chronic diarrhea or thrombotic disease as
well as in a group of healthy Greyhounds. We hypothe-
sized that hypofolatemia is frequently observed in Grey-
hounds and that hypocobalaminemia, hypofolatemia, or
both are associated with increased HCY concentrations
in this breed. We further hypothesized that, compared
to healthy Greyhounds, hyperhomocysteinemia would
be more common in those dogs with chronic gastroin-
testinal disease or thrombotic disease.
Materials and Methods
Ethics Approval
According to the guidelines of the clinical research review com-
mittee (2007–2011) and the Institutional Animal Care and Use
Committee (2011–2013) at Texas A&M University (TAMU), for-
mal ethical approval of this study and written owner consent were
not needed because all dogs included in the study had been sam-
pled during routine diagnostic investigation and no additional
samples had been obtained or interventions performed for the pur-
pose of the study.
Study Populations and Sampling
Prevalence of Hypofolatemia. Sample submissions from Grey-
hounds (n = 423) to the Gastrointestinal Laboratory at TAMU
between March 2006 and February 2010 (48 months) for analysis
of serum cobalamin and folate concentrations were retrospectively
reviewed. Hypocobalaminemic Greyhounds (serum cobalamin con-
centration <251 ng/L; reference interval [RI], 251–908 ng/La ) were
identiﬁed and investigated for the proportion of dogs with concur-
rent hypofolatemia (serum folate concentration <7.7 lg/L; RI,
7.7–24.4 lg/La). Data extracted from the laboratory database
included breed, age, sex, and serum concentrations of cobalamin
and folate. Information about the submitting veterinarian and the
name of the dog and owner was used to exclude multiple submis-
sions from the same dog.
Frequency of Hyperhomocysteinemia. For the second part of the
study, surplus serum samples from 82 Greyhounds, submitted to
the Gastrointestinal Laboratory at TAMU between October 2012
and March 2013 (6 months), were used to measure serum HCY
concentrations (RI, 5.0–22.1 lmol/L20) in addition to the serum
concentrations of cobalamin and folate. Data extracted from the
laboratory database included breed, age, sex, and the serum con-
centrations of cobalamin and folate. Information about the veteri-
narian and the name of the dog and owner was used to ensure
that serial results were removed and only 1 sample included from
each dog. Furthermore, all owners or veterinarians of the dogs
included in this part of the study were contacted to verify the sig-
nalment for each dog.
Serum HCY Concentrations in Greyhounds with Thrombosis or
Chronic Diarrhea and from Healthy Greyhounds. For the third part
of the study, serum samples from Greyhounds with a history of
thrombotic events (n = 8; 6 dogs with thrombotic events involving
the central nervous system and 1 dog each with a thrombotic event
involving a central blood vessel [aorta] or smaller peripheral ves-
sels [blood supply of a limb]), Greyhounds with chronic diarrhea
(n = 30), and healthy control Greyhounds enrolled in a blood
donor program (n = 16) were collected at the Ohio State Univer-
sity (OSU; n = 27) and Texas A&M University (TAMU; n = 27)
between January 2007 and September 2013 (80 months). Serum
samples obtained from Greyhounds at OSU were shipped as 1
batch to TAMU overnight on ice packs, and all serum specimens
were stored at 80°C until further analysis of serum HCY, cobal-
amin, and folate at the TAMU Gastrointestinal Laboratory.
Information about the Greyhounds recruited at OSU (n = 27;
all 3 groups of Greyhounds) was extracted from the dogs’ medical
records. Retrieval of information about the dogs recruited at
TAMU (n = 27; only Greyhounds with chronic diarrhea) was by
phone contact with the veterinarian and return of a completed
standard study questionnaire (by fax or email) designed to verify
the dog’s signalment and evaluate its medical history and current
health status. Health status in the control group of Greyhounds
was determined on the basis of historical information and the
results of a complete physical examination and routine blood work
(hematologyb and serum biochemistry proﬁlec ).
Quantification of Serum Cobalamin, Folate, and HCY
Concentrations
Serum cobalamin and folate concentrations were measured by
means of validated automated solid-phase chemiluminescence
assays.d,e The lower detection limits of the assays are 150 ng/L
and 1.0 lg/L, respectively.23
Serum HCY concentrations were measured by use of an
established and validated stable isotope dilution gas chromatog-
raphy-mass spectrometry (GC/MS) assay as previously
described.24 Brieﬂy, standard calibration solutions (200, 100, 50,
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25, 12.5, 6.3, and 3.13 lmol/L) were prepared fresh daily with
nonisotopic homocystinef in 1 M HCl, and deuterium-labeled
homocystine isotopeg (100 lmol/L) served as an internal stan-
dard. After incubation of serum samples in deuterated homocys-
tine: NaOH (3.4 mM): dithiothreitol (34% [w/v]): ddH2O (26.7:
3.3: 3.4: 66.6) for 1 hour at 37°C, HCY was extracted with a
chromatography columnh packed with an ion exchange resini
and conditioned with methanol/ddH2O. After elution of HCY
with 0.4 M acetic acid in methanol, samples were vacuum-dried
in nitrogen at 64°C for 30 minutes. Homocysteine then was
derivatized by silylation with N-methyl-N-tert-butyldimethylsilyl-
triﬂuoroacetamide: acetonitrile (50 : 50) for 30 minutes at 64°C.
Samples were analyzed in a gas chromatographj with a mass-
selective detector,k with samples being injected into a capillary
columnl at a temperature of 250°C and helium used as carrier
gas. The starting temperature was 140°C and was followed by a
linear temperature ramp of 30°C/min to 300°C, then 20°C/min
to 325°C, and a hold time of 62 seconds. The mass spectrome-
ter source was operated at 230°C, and HCY and its deuterated
isotope were quantiﬁed by the ions at m/z 420 and 424, respec-
tively. All samples were extracted, derivatized, and analyzed in
batches of 20 samples each. This assay has a lower detection
limit of 5.0 lmol/L.
Statistical Analyses
Measurements for continuous variables were ﬁrst investigated
for normality of their distribution by a Shapiro-Wilk W test.
Summary statistics for continuous variables are presented as
medians and interquartile ranges (IQR) for nonparametric data
and as means  standard deviations (SD) for parametric
data. Categorical variables are presented as proportions or
percentages.
A Fisher’s exact test, with calculation of the odds ratio (OR)
and 95% conﬁdence interval (95% CI), was used to test the possi-
bility of an association between: (1) hypocobalaminemia and con-
current hypofolatemia, (2) hyperhomocysteinemia and either
hypocobalaminemia or hypofolatemia alone, and (3) hyperhomo-
cysteinemia and concurrent hypocobalaminemia and hypofo-
latemia. A Mann-Whitney U-test was utilized to compare serum
HCY concentrations in hypocobalaminemic and hypofolatemic
Greyhounds with those in normocobalaminemic and normofo-
latemic Greyhounds.
Age and serum HCY, cobalamin, and folate concentrations
were compared among the 3 groups of Greyhounds by an
ANOVA or a nonparametric Kruskal-Wallis test, as applicable.
Proportions of categorical variables were compared among the
diﬀerent groups of dogs by use of a chi-square test. Serum
HCY concentrations also were assessed with respect to other
continuous variables. Correlation analysis was performed to test
for any possible correlation between the serum concentration of
HCY and the 2 B vitamins (folate and cobalamin) in all Grey-
hounds and between serum HCY concentrations and 14 clinico-
pathologic variables (RBC count, hemoglobin concentration,
platelet count, WBC count, serum concentrations of BUN, crea-
tinine, phosphorus, total protein, albumin, globulin, and choles-
terol, serum Ca9P product, and serum ALT and AST activities)
previously shown to have breed-speciﬁc deviations from generic
canine reference intervals25 in 19 Greyhounds by calculating a
Spearman rank-sum correlation coeﬃcient q for nonparametric
data. For all testing, signiﬁcance was set at a P < .05, and the
cutoﬀ for statistical signiﬁcance was adjusted according to the
number of correlations (n = 14) from P < .05 to P < .0035 by a
Bonferroni correction for multiple statistical comparisons.m A
commercially available software packagen was used for all statis-
tical analyses.
Results
Prevalence of Hypofolatemia
In the database review, hypofolatemia was identiﬁed
in 172 of the 423 serum samples (41%) from Grey-
hounds that were submitted for serum cobalamin and
folate analysis over a 48-month period; hypofolatemia
was more frequently observed in hypocobalaminemic
Greyhounds (82/168, 49%) than in normocobalamine-
mic Greyhounds (90/255, 35%; odds ratio [OR] [95%
CI]: 1.8 [1.2–2.6]; P = .0064; Fig 1).
Frequency of Hyperhomocysteinemia
Four of the 82 dogs considered for inclusion in this
part of the study were identiﬁed as Italian Greyhounds
and thus were excluded from further analyses. Hyperho-
mocysteinemia was identiﬁed in 53 of the 78 serum
samples (68%) from Greyhounds that were submitted
for cobalamin and folate analysis over a 6-month per-
iod; hyperhomocysteinemia was detected in 11 of 12
(92%) hypocobalaminemic and hypofolatemic Grey-
hounds and in 28 of 46 (61%) normocobalaminemic
and normofolatemic Greyhounds (P = .0806). Although
not statistically signiﬁcant, serum HCY concentrations
were numerically higher in hypocobalaminemic and
hypofolatemic Greyhounds (n = 12; median, 42.6 lmol/L;
interquartile range [IQR], 33.7–55.0 lmol/L) compared
to normocobalaminemic and normofolatemic Grey-
hounds (n = 46; median, 30.8 lmol/L; IQR, 15.0–
56.0 lmol/L; P = .1476).
Regardless of the serum folate concentration, hyper-
homocysteinemia was identiﬁed in 15 of 20 (75%)
hypocobalaminemic Greyhounds and in 38 of 58 (64%)
normocobalaminemic Greyhounds (P = .5808). If only
serum folate concentrations were considered for the
Fig 1. Prevalence of hypofolatemia in Greyhounds (n = 423).
Shown are the proportions of hypofolatemic (n = 172, 41%; black
bars) or normofolatemic Greyhounds (n = 251, 59%; gray bars)
divided by concurrent hypocobalaminemia (low COB) or normo-
cobalaminemia (normal COB).
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classiﬁcation of dogs (regardless of the serum cobalamin
concentration), hyperhomocysteinemia was identiﬁed
more frequently in hypofolatemic Greyhounds (21/24,
88%) than in Greyhounds with normofolatemia (32/54,
59%; OR [95% CI], 4.8 [1.3–18.1]; P = .0175). Neither
age (P = .6105) nor sex (P = .1031) had an eﬀect on
serum HCY concentrations, although serum concentra-
tions were numerically higher in males (median,
40.9 lmol/L; IQR, 25.0–60.9 lmol/L) compared to
female Greyhounds (median, 30.6 lmol/L; IQR, 13.0–
53.3 lmol/L). Serum HCY concentrations were all
<9.2 lmol/L (median, 8.0 lmol/L; IQR, 7.1–8.4 lmol/L)
in the 4 Italian Greyhounds identiﬁed that were
excluded from the study.
Comparison of Serum HCY Concentrations between
Diseased Groups and Healthy Greyhounds
In the group comparison part of the study, serum
HCY concentrations diﬀered among the 3 diﬀerent
groups of Greyhounds (P = .0012) (Table 1), with
healthy Greyhounds having signiﬁcantly higher serum
HCY concentrations than Greyhounds with diarrhea
(P < .01) or thrombosis (P < .05; Fig 2). All healthy
Greyhounds had serum HCY concentrations above the
upper limit of the previously reported non-breed-speciﬁc
RI (>22.1 lmol/L), whereas 21 of 30 (70%) of the dogs
with chronic diarrhea and 6 of 8 (75%) of those with
thrombosis were found to be hyperhomocysteinemic in
relation to that RI.
Serum cobalamin and folate concentrations did not
diﬀer among the 3 groups of Greyhounds (both:
P > .05). Serum cobalamin concentrations were within
the RI in all healthy Greyhounds, whereas 10 of 30
(33%) of the Greyhounds with chronic diarrhea and 1
of 8 (13%) of those dogs with thrombosis were
hypocobalaminemic. Hypofolatemia was associated with
hypocobalaminemia (P = .0459) and was detected in 10
of 16 (63%) healthy controls, 11 of 30 (37%) Grey-
hounds with chronic diarrhea, and in 3 of 8 (38%)
Greyhounds with thrombosis.
No correlation was observed between the serum
HCY and cobalamin concentrations (P = .6008), but an
inverse correlation was identiﬁed between the concen-
trations of HCY and folate in serum (q = 0.28;
P = .0386) when samples from dogs of all groups were
analyzed together (Fig 3). Serum HCY concentrations
also were negatively correlated with age (q = 0.42;
95% CI, 0.62 to 0.17; P = .0020), but Greyhounds
with thrombosis were signiﬁcantly older in this study
than those dogs in the control group (P < .01). Serum
HCY concentrations were numerically higher in male
dogs (n = 23; median, 56.7 lmol/L; IQR, 33.6–
75.4 lmol/L) than in female dogs (n = 31; median,
35.8 lmol/L; IQR, 29.5–52.5 lmol/L), but the diﬀer-
ence did not reach statistical signiﬁcance (P = .0643).
Relevant clinicopathologic variables in 19 of the 54
Greyhounds are summarized in Table 2. Evaluation of
the relationship between serum HCY concentrations
and selected clinicopathologic variables showed a posi-
tive association between the serum concentrations of
HCY and albumin (q = 0.66; 95% CI, 0.28 to 0.86;
P = .0022) but no other signiﬁcant correlations (for all:
P > .0035). Only 1 Greyhound (with thrombosis) was
found to be hypoalbuminemic (serum albumin
Fig 2. Serum homocysteine (HCY) concentrations in 3 groups of
Greyhounds (n = 54). Serum HCY concentrations were signiﬁ-
cantly higher in healthy Greyhounds (mean  SD: 65.2 
24.2 lmol/L) compared to those in Greyhounds with diarrhea
(39.7  21.7 lmol/L; P < .01) or thrombosis (36.7  22.1 lmol/L;
P < .05). Solid lines: means; symbols (●, ■, and ▲): serum HCY
concentrations in individual dogs; gray-shaded area between
dashed lines: previously reported non-breed-speciﬁc reference inter-
val (5.0–22.1 lmol/L).
Fig 3. Relationship between the serum concentration of homo-
cysteine (HCY) and folate in Greyhounds with chronic diarrhea or
thrombosis (n = 38) and healthy Greyhounds (n = 16). An inverse
correlation was detected between the concentration of HCY and
folate in serum (Spearman q = 0.28; 95%CI: 0.52 to 0.01;
P = .0386). Symbols (●): serum HCY and folate concentrations in
individual dogs; dotted line: regression line; solid lines: 95% conﬁ-
dence interval of the regression line.
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concentration, 2.6 g/dL; RI, 2.9–4.2 g/dL). This dog
was panhypoproteinemic (serum globulin concentration,
2.0 g/dL; RI, 2.2–2.9 g/dL) and was 1 of the 2 dogs in
this group with a normal serum HCY concentration.
Hypoglobulinemia was found in 11 of the 19 Grey-
hounds (58%) from which a serum biochemistry panel
was performed. Serum concentrations of HCY were not
associated with serum creatinine concentrations
(P = .2212).
Discussion
Our study evaluated serum folate, cobalamin, and
HCY concentrations in a large population of Grey-
hounds. Similar to hypocobalaminemia,1 hypofolatemia
also was found to occur frequently in Greyhounds, with
combined B hypovitaminoses being more commonly
seen than isolated hypocobalaminemia or hypofo-
latemia. Although this ﬁnding may reﬂect small intesti-
nal malabsorption of both B vitamins as a result of
chronic disease,2 increased demand for these vitamins,
or the possibility that systemic concentrations of these
vitamins may not reﬂect their intracellular levels, is a
possible alternative explanation.
Although hyperhomocysteinemia was observed in
hypofolatemic and hypocobalaminemic Greyhounds in
our study, it also was present in Greyhounds with nor-
mal serum concentrations of both B vitamins. Our
study did identify an association between hypofolatemia
and hyperhomocysteinemia, whereas hypocobalamine-
mia and hyperhomocysteinemia were not statistically
related. These ﬁndings also suggest that hyperhomocys-
teinemia in Greyhounds occurs as a consequence of the
lack of these 2 B vitamins, in particular vitamin B9
(folate), at the intracellular level rather than merely the
systemic level.
In keeping with the ﬁnding that hyperhomocysteine-
mia is associated with folate status and oxidative
stress,4,6,7 the inverse correlation observed in our study
between serum concentrations of HCY and folate, but
not cobalamin, agrees with ﬁndings in people with
hypertension,26 cerebral venous thrombosis,27 epilepsy,28
and inﬂammatory bowel disease.29,30 However, these
ﬁndings are in contrast with results in dogs with sys-
temic inﬂammatory response syndrome or sepsis,23 dogs
with chronic enteropathy,31 and in some people with
inﬂammatory bowel disease.11
The relationship with hypofolatemia in our study
suggests that hyperhomocysteinemia in Greyhounds
could be a cause or consequence of pathologic condi-
tions (e.g, decreased methylation capacity). However,
whether the hyperhomocysteinemia is associated with
an increased risk of clinically relevant pathology (such
as an increased risk of vascular dysfunction,32 thrombo-
sis, or other cardiovascular disease) or represents a
peculiarity in the Greyhound breed, similar to other
breed-speciﬁc clinicopathological characteristics likely
associated with the unique physiology of this breed,25,33
cannot be evaluated by the results of our study and
requires further investigation. Thus, the clinical rele-
vance and potential need for B vitamin supplementation
(particularly folic acid) in Greyhounds requires further
study because clinical trials of HCY-lowering treatment
in people produced mixed results and did not indicate a
clear clinical beneﬁt for all outcomes evaluated.4,5,7,8
Nevertheless, the ﬁnding of hyperhomocysteinemia in
all healthy Greyhounds in this study suggests that this
breed might be explored as a novel spontaneous canine
model to further investigate hyperhomocysteinemia in
humans. However, further research is needed to charac-
terize this model.
The transsulfuration (vitamin B6-dependent) pathway
presents a way to compensate for decreased remethyla-
tion of HCY to methionine. However, vitamin B6 con-
centrations or the individual methylation potential7 was
not determined as part of our investigation. Whether
the transsulfuration pathway plays a role in the hyper-
homocysteinemia observed in Greyhounds warrants fur-
ther study. Also, evaluation of potentially synergistic
genetic variations (e.g, enzymes involved in the metabo-
lism of HCY: methylenetetrahydofolate reductase,
methionine synthase, methionine synthase reductase, or
cystathionine b-synthase and their cofactors) as well as
Table 1. Characteristics of healthy Greyhounds and Greyhounds with chronic diarrhea or thrombosis (n = 54).
Characteristic
Group
Healthy Controls Diarrhea Thrombosis P-value‡
Total number, n 16 30 8 –
Age in years, median (IQR)¶ 5 (4–7)A 8 (5–10)A,B 10 (9–11)B .0055§
Sex, male/female 8/8 19/11 4/4 .6159
Serum HCY concentration
(in lmol/L), median (IQR)¶
66.9 (46.3–83.1)A 36.1 (21.1–54.4)B 32.3 (26.5–41.6)B .0012§
Serum folate concentration
(in lg/L), median (IQR)
7.1 (6.6–10.0) 9.2 (5.6–13.2) 9.7 (6.7–13.1) .6907
Serum cobalamin concentration
(in ng/L), median (IQR)
362 (331–449) 316 (246–435) 339 (280–408) .2554
n, count; IQR, interquartile range; HCY, homocysteine.
‡Global P-value.
§Signiﬁcant diﬀerence among the 3 groups of Greyhounds.
–For each parameter, medians (IQR) not sharing a common superscript are signiﬁcantly diﬀerent at P < .05.
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nutritional (e.g, dietary protein content, supplementa-
tion) and environmental factors is warranted in Grey-
hounds with hyperhomocysteinemia.
Despite relative hypocoagulability,25,34 the activity of
plasma antithrombin has been shown to be decreased
and von Willebrand factor collagen binding to be
increased in some Greyhounds,25 potentially rendering
homeostasis a delicate balance between a state of
“downregulated” or “upregulated” coagulation in this
breed. A procoagulant eﬀect of hyperhomocysteinemia
(e.g, induction of tissue factor, activation of factor V,
and inhibition of protein C activation and von Wille-
brand factor secretion) has been identiﬁed in people,35–38
but routine hemostasis or platelet function testing,
thromboelastograms, or evaluation of speciﬁc coagula-
tion factors or coagulation inhibitors were not included
in this study. Thus, the possibility of an association
between hyperhomocysteinemia and markers of coagu-
lation, ﬁbrinolysis, and endothelial cell activation and
vascular dysfunction in Greyhounds needs to be further
investigated. Also, a possible eﬀect of systemic arterial
hypertension on serum HCY concentrations in Grey-
hounds has not been evaluated and warrants further
study.
An unexpected ﬁnding in our study was a higher
frequency of hyperhomocysteinemia in healthy Grey-
hounds compared to Greyhounds with chronic diar-
rhea or thrombotic disease. The positive correlation of
serum HCY with serum albumin concentration in
Greyhounds observed in our study agrees with a previ-
ous investigation by this group in dogs with
hypocobalaminemia suspected to be associated with
chronic enteropathies22 and in people with end-stage
renal disease39 or nephrotic syndrome,40 but it con-
trasts with ﬁndings in people with inﬂammatory bowel
disease.11 A possible explanation for these ﬁndings is
that the majority (approximately 90%) of systemic
total HCY has been shown to be bound to albumin,
with the remainder being bound to globulins.41 Thus,
protein-losing diseases (e.g, protein-losing enteropathy
or nephropathy), which were also shown to create a
hypercoagulable state,42,43 may be associated with a
lower degree of hyperhomocysteinemia than expected.
Nevertheless, the percentage of hyperhomocysteinemic
Greyhounds with chronic diarrhea in this study (70%)
was similar to that in people in inﬂammatory bowel
disease (50–60%).11,44
In humans, hyperhomocysteinemia also can be associ-
ated with decreased glomerular ﬁltration rate in patients
with renal insuﬃciency.5,45 Although staging of possible
chronic kidney disease was not included in our study, a
correlation between serum HCY and serum creatinine
concentration was not observed, and healthy Grey-
hounds previously were reported to have increased
glomerular ﬁltration rates.46 Furthermore, our study
showed that both age and sex do not appear to aﬀect
serum HCY concentrations in Greyhounds, which is
dissimilar to studies in people where a predominance of
hyperhomocysteinemia has been reported in older peo-
ple and in males.5,8 However, the possibility must be
considered that the signiﬁcant age diﬀerences seen
among the 3 groups of Greyhounds may have had a
confounding eﬀect on the relationship between aging
and serum HCY concentrations. Also, with the large
percentage of neutered Greyhounds included in our
study (approximately 90%), an eﬀect of sex hormones
on serum HCY concentrations may have been masked.
A high frequency of concurrent hypoglobulinemia and
normoalbuminemia as seen in our study also is consis-
tent with previous reports in Greyhounds.33
We acknowledge that our study suﬀered from some
limitations. First, the frequency of hypofolatemia, and
also hypocobalaminemia, may have been overestimated
because of selection bias with the use of data and
Table 2. Relevant clinicopathologic data in 19 Greyhounds.
Parameter Median (IQR) Reference Interval (RI)b Values Below RI Values Above RI
Hematologya
RBC count (91012/L) 7.9 (7.3–8.3) 4.8–8.1 0 (0%) 5 (39%)
Hb concentration (g/dL) 18.3 (17.9–19.5) 12.1–18.8 0 (0%) 6 (46%)
Platelet count (9109/L) 171 (153–186) 108–433 0 (0%) 0 (0%)
WBC count (9109/L) 5.6 (4.3–6.4) 4.1–15.4 3 (23%) 0 (0%)
Clinical chemistry
BUN (mg/dL) 21.0 (17.5–22.5) 5.0–20.0 0 (0%) 10 (53%)
Creatinine (mg/dL) 1.7 (1.5–2.1) 0.6–1.6 0 (0%) 11 (58%)
Phosphorus (mg/dL) 3.3 (3.1–3.7) 3.2–8.1 9 (47%) 0 (0%)
Ca9P product (mg2/dL2) 33.2 (30.5–36.6) ≤60 – 1 (5%)
Total protein (g/dL) 5.7 (5.6–6.1) 5.1–7.1 3 (16%) 0 (0%)
Albumin (g/dL) 3.6 (3.3–3.7) 2.9–4.2 1 (5%) 0 (0%)
Globulin (g/dL) 2.1 (1.9–2.3) 2.2–2.9 11 (58%) 0 (0%)
Cholesterol (mg/dL) 174 (144–190) 80–315 0 (0%) 0 (0%)
ALT activity (U/L) 46 (39–62) 10–55 0 (0%) 7 (37%)
AST activity (U/L) 42 (32–49) 12–40 0 (0%) 10 (53%)
IQR, interquartile range; Hb, hemoglobin, RBC, red blood cell, BUN, blood urea nitrogen, ALT, alanine aminotransferase; AST, aspar-
tate aminotransferase.
aOnly available for n = 13 dogs.
bOSU Clinical pathology RI (not breed-speciﬁc).
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samples from a laboratory database. The specimens
from Greyhounds had been submitted to the laboratory
for cobalamin and folate analysis, but the speciﬁc indi-
cation in individual dogs could not be evaluated. Thus,
the proportion of hypofolatemic or hypocobalaminemic
dogs or both may not reﬂect the general Greyhound
population. Second, the possibility of B vitamin supple-
mentation in individual dogs cannot be excluded. Third,
diﬀerent underlying conditions leading to thrombosis
(e.g, protein-losing diseases) could present a confound-
ing factor for the group of dogs with thrombotic events.
Consequently, the correlation with hyperhomocysteine-
mia in this study could be coincidental. Fourth, the
intra- and interindividual biologic variation as well as
the minimum critical diﬀerence or reference change
value for serum HCY concentrations has not been eval-
uated and is unknown in dogs. Lastly, quantiﬁcation of
serum methylmalonic acid would have been useful to
evaluate the cellular availability of cobalamin but could
not be performed in this retrospective study because of
the poor long-term stability of methylmalonic acid in
serum samples.
In conclusion, hypofolatemia in Greyhounds was
associated with hypocobalaminemia, and increased
serum HCY concentrations were observed in hypofo-
latemic and hypocobalaminemic Greyhounds, but also
in Greyhounds with normal serum concentrations of
both B vitamins, suggesting a lack of these vitamins at
the intracellular rather than the serum concentration.
The functional implication of these ﬁndings in Grey-
hounds warrants further study. Healthy Greyhounds
had higher serum HCY concentrations than Grey-
hounds with chronic diarrhea or thrombotic disease,
and all healthy Greyhounds were hyperhomocysteine-
mic, suggesting that hyperhomocysteinemia in healthy
Greyhounds might represent a novel spontaneous
canine model to further investigate hyperhomocysteine-
mia in humans. Additional studies are warranted to
characterize the potential of this model.
Footnotes
a Gastrointestinal Laboratory at Texas A&M University (available
at: http://vetmed.tamu.edu/gilab/service/assays/b12folate)
b Cell-Dyn 3500 Automated Hematology Analyzer, Abbott Diag-
nostics, Lake Forest, IL
c Cobas c501 Clinical Chemistry Analyzer, Roche Diagnostics,
Indianapolis, IN
d Immulite2000, Vitamin B12, Siemens Healthcare Diagnostics
Inc., Deerﬁeld, IL
e Immulite2000, Folic Acid, Siemens Healthcare Diagnostics Inc.,
Deerﬁeld, IL
f
L-homocystine, Sigma Chemical Co, St. Louis, MO
g DL-Homocystine-3,3,3,3,4,4,4,4-d8, C/D/N Isotopes Inc, Pointe-
Claire, QC, Canada
h Poly-Prep disposable chromatography column, Bio-Rad, Her-
cules, CA
i AG1-MP ion exchange resin, Bio-Rad, Hercules, CA
j Agilent model 7890A gas chromatograph, Agilent Technologies,
Santa Clara, CA
k Agilent 5975C Series mass-selective detector, Agilent Technolo-
gies, Santa Clara, CA
l DB-1 ms 100% dimethylpolysiloxane column, Agilent Technolo-
gies, Santa Clara, CA
m Bonferroni correction for multiple statistical comparisons
(http://www.quantitativeskills.com/sisa/calculations/bonfer.htm)
n GraphPad Prism v6, GraphPad Software, La Jolla, CA
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